Natera Inc (NASDAQ:NTRA) Chairman Matthew Rabinowitz sold 1,418 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $35,152.22. Following the sale, the chairman now owns 1,286,612 shares in the company, valued at approximately $31,895,111.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Matthew Rabinowitz also recently made the following trade(s):
- On Monday, April 15th, Matthew Rabinowitz sold 614 shares of Natera stock. The stock was sold at an average price of $20.25, for a total value of $12,433.50.
Shares of NTRA traded down $0.63 during trading hours on Friday, reaching $24.53. The company’s stock had a trading volume of 8,548 shares, compared to its average volume of 564,092. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -11.41 and a beta of 1.43. Natera Inc has a 1-year low of $11.08 and a 1-year high of $29.62. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.73.
Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $66.82 million for the quarter, compared to the consensus estimate of $66.40 million. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. Equities research analysts expect that Natera Inc will post -2.17 earnings per share for the current fiscal year.
Several research firms have issued reports on NTRA. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, March 21st. BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 12th. Piper Jaffray Companies boosted their price objective on Natera from $23.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of Natera in a report on Monday, March 11th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.25.
Institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC increased its holdings in shares of Natera by 47.2% in the 4th quarter. Squarepoint Ops LLC now owns 149,160 shares of the medical research company’s stock valued at $2,082,000 after purchasing an additional 47,860 shares during the period. Tygh Capital Management Inc. increased its holdings in shares of Natera by 18.0% in the 4th quarter. Tygh Capital Management Inc. now owns 414,726 shares of the medical research company’s stock valued at $5,790,000 after purchasing an additional 63,155 shares during the period. Perkins Capital Management Inc. increased its holdings in shares of Natera by 121.3% in the 1st quarter. Perkins Capital Management Inc. now owns 129,900 shares of the medical research company’s stock valued at $2,679,000 after purchasing an additional 71,200 shares during the period. RMB Capital Management LLC acquired a new position in shares of Natera in the 4th quarter valued at about $1,017,000. Finally, Principal Financial Group Inc. increased its holdings in shares of Natera by 60.3% in the 4th quarter. Principal Financial Group Inc. now owns 233,205 shares of the medical research company’s stock valued at $3,255,000 after purchasing an additional 87,750 shares during the period. Institutional investors own 80.32% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Natera Inc (NASDAQ:NTRA) Chairman Sells $35,152.22 in Stock” was originally reported by Riverton Roll and is the sole property of of Riverton Roll. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://rivertonroll.com/news/2019/06/14/natera-inc-nasdaqntra-chairman-sells-35152-22-in-stock.html.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: What are economic reports?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.